The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it is a matter of tracking…
Posts published in “Insights”
This article was originally published by Christopher M. Holman* in Intellectual Property Watch under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Despite the important role of intellectual property rights in…
This paper was originally published by Maya Tannoury and Zouhair Attieh in Current Therapeutic Research under a creative commons license. Abstract Emerging markets represent an exceptional opportunity for the pharmaceutical…
When drugs are taken off the market because of concerns about their safety, it makes headlines. To access DrugPatentWatch’s list of discontinued drugs try a free trial or contact us…
Here’s a copy of the recent talk on Finding and Evaluating Branded and Generic Market Entry Opportunities. It’s based on the book Make Better Decisions, which distills insights gained from…
You would be surprised to find out just how many questions are answered by the analysis of the relationship that emerges between generic competition and drug prices. For manufacturers and…
Valuing pharma companies isn’t the same as valuing non-pharma companies, for several reasons. Traditional business considerations are compounded by patent law and FDA approval processes when evaluating the investment potential of…
Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about the sustainability and profitability of major generics companies. But some…
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A.van Bodegraven, Nanne K.H. de Boer, and Chris J.J. Mulder in Drug Discovery Today Volume 23, Issue 1, January…
When referring to “big data” in the context of the drug industry, one should essentially think of a collection of datasets with the help of which companies are able to…